Erudio Healtherudio.com
Sponsor
MedSIR trials: what clinicians said in public
No HCP commentary report on a trial sponsored by MedSIR yet. Erudio has found public clinician commentary on 7 clinical trials sponsored by MedSIR, including PALMIRA, PECATI, PHERGain and TUXEDO-3. Each trial's page lists the podcasts, videos and posts found so far and the price of a report.
Listed by lead sponsor as registered on ClinicalTrials.gov (MedSIR). A trial led by a partner or a research group is on that sponsor's page. Only trials with public clinician commentary found are listed, not every trial the sponsor runs.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| No report yetTrials with public commentary we haven't built a report for. Size is an estimate of the verified statements the commentary we've indexed so far will yield; final coverage is set when we build the report, within 24 hours of your confirmed order. You never pay more than quoted: a report delivered at a smaller size costs that size's price. Some can also be requested as a free preview. | |||||||
| PHERGain NCT03161353 · MedSIR DeepView → | HER2-positive early breast cancer | Phase 2 | Deep | View | |||
| TUXEDO-3 NCT05865990 · MedSIR DeepView → | breast cancer/NSCLC brain metastases; solid tumor leptomeningeal disease | Phase 2 | Deep | View | |||
| PALMIRA NCT03809988 · MedSIR DeepView → | hormone receptor-positive HER2-negative advanced breast cancer | Phase 2 | Deep | View | |||
| PECATI NCT04710628 · MedSIR DeepView → | pretreated metastatic B3 thymoma and thymic carcinoma | Phase 2 | Deep | View | |||
| DEMETHER NCT06172127 · MedSIR DeepView → | HER2-positive unresectable locally recurrent or metastatic breast cancer | Phase 2 | Deep | View | |||
| DEBBRAH NCT04420598 · MedSIR StandardView → | HER2-positive/HER2-low breast cancer with central nervous system involvement | Phase 2 | Standard | View | |||
| ADELA NCT06382948 · MedSIR StandardView → | ESR1-mutated ER+/HER2- advanced breast cancer after CDK4/6 inhibitors | Phase 3 | Standard | View | |||